Table 4.
Distribution of SNPs in AXIN1 between patients' characteristics and their association with bladder cancer risk.
| Characteristics | rs12921862 | rs1805105 | rs370681 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Genotype | P valuea | Genotype | P valuea | Genotype | P valuea | ||||
| CC | CA/AA | TT | TC/CC | CC | CT/TT | ||||
| Age | |||||||||
| ≤64 years old | 102 (70.8%) | 42 (29.2%) | 0.04 | 85 (59%) | 59 (41%) | 0.10 | 56 (40.3%) | 83 (59.7%) | 0.83 |
| >64 years old | 103 (59.9%) | 69 (40.1%) | 83 (48.8%) | 87 (51.2%) | 58 (35.8%) | 104 (64.2%) | |||
| Sex | |||||||||
| Male | 164 (65.9%) | 85 (34.1%) | 0.77 | 128 (51.6%) | 120 (48.4%) | 0.47 | 88 (37.5%) | 147 (62.5%) | 0.96 |
| Female | 41 (61.2%) | 26 (38.8%) | 40 (60.6%) | 26 (39.4%) | 26 (39.4%) | 40 (60.6%) | |||
| Smoke | |||||||||
| Smoker | 111 (68.1%) | 52 (31.9%) | 0.4 | 80 (49.4%) | 82 (50.6%) | 0.25 | 58 (37.7%) | 96 (62.3%) | 0.90 |
| Nonsmoker | 94 (61.4%) | 59 (38.6%) | 88 (57.9%) | 64 (42.1%) | 56 (38.1%) | 91 (61.9%) | |||
| Tumor stage | |||||||||
| MIBC | 98 (65.3%) | 52 (34.7%) | 0.94 | 74 (49.7%) | 75 (50.3%) | 0.97 | 48 (33.1%) | 97 (66.9%) | 0.44 |
| NMIBC | 107 (64.5%) | 59 (35.5%) | 94 (57%) | 71 (43%) | 66 (42.3%) | 90 (57.7%) | |||
| Tumor grade | |||||||||
| High grade | 120 (65.9%) | 62 (34.1%) | 0.49 | 87 (48.3%) | 93 (51.7%) | 0.18 | 56 (32%) | 119 (68%) | 0.04 |
| Low grade | 85 (63.4%) | 49 (36.6%) | 81 (60.5%) | 53 (39.5%) | 58 (46%) | 68 (54%) | |||
| Recurrence | |||||||||
| Recurrent | 59 (63.4%) | 34 (36.6%) | 0.84 | 50 (53.8%) | 43 (46.2%) | 0.97 | 32 (36%) | 57 (64%) | 0.40 |
| Nonrecurrent | 146 (65.5%) | 77 (34.5%) | 118 (53.4%) | 103 (46.6%) | 82 (38.7%) | 130 (61.3%) | |||
| Metastasis | |||||||||
| Metastatic | 31 (62%) | 19 (38%) | 0.68 | 24 (49%) | 25 (51%) | 0.70 | 19 (40.4%) | 28 (59.6%) | 0.07 |
| Nonmetastatic | 174 (65.4%) | 92 (34.6%) | 144 (54.3%) | 121 (45.7%) | 94 (37.1%) | 159 (62.9%) | |||
Italic values indicate a significant difference at the 5% level. aAdjusted by age, sex, smoking status, tumor stage, tumor grade, recurrence status, and metastasis status.